Patents by Inventor MICHAEL HAHNE

MICHAEL HAHNE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240085518
    Abstract: Described herein is a mobile device with an optical detector including: at least one illumination source adapted to generate at least one illumination pattern for illuminating an object, where the illumination pattern includes a regular and/or constant and/or periodic pattern; at least one sensor element having a matrix of optical sensors, the optical sensors each having a light-sensitive area, where each optical sensor is configured to generate at least one sensor signal in response to an illumination of the light-sensitive area by at least one light beam propagating from the object to the detector; and at least one evaluation device adapted to determine at least one region of interest.
    Type: Application
    Filed: September 28, 2023
    Publication date: March 14, 2024
    Inventors: Michael EBERSPACH, Thomas OHMER, Robert SEND, Christian LENNARTZ, Christopher HAHNE, Stefan HENGEN, Sebastian VALOUCH, Christoph LUNGENSCHMIED, Ingmar BRUDER, Wilfried HERMES, Celal Mohan OEGUEN, Christian Daniel SCHILDKNECHT, Peter SCHILLEN, Patrick SCHINDLER, Peter FEJES
  • Patent number: 11649211
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: May 16, 2023
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Romain Najman, Florence Mahuteau, Didier Scherrer, Karim Chebli, Michael Hahne
  • Publication number: 20210087145
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Application
    Filed: December 7, 2020
    Publication date: March 25, 2021
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, Romain NAJMAN, Florence MAHUTEAU, Didier SCHERRER, Karim CHEBLI, Michael HAHNE
  • Patent number: 10435370
    Abstract: The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxy! group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (Ci-C3)fluoroalkyl group, a —O—P(?O)—(OR3XOR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among: (IIa), (IIIa) or anyone of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of an inflammatory disease.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: October 8, 2019
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Romain Najman, Florence Mahuteau, Didier Scherrer, Karim Chebli, Michael Hahne
  • Publication number: 20190054593
    Abstract: Disclosed is an invention that offers improvements to machines used for power floor buffing, grinding, and polishing including: a dust containment system which utilizes a single shroud with an attached lower brush to fully enclose the top and sides of a rotating implement whereas said shroud is spring loaded and allowed to move vertically and tilt in order to maintain firm contact with the floor at all times and prevent escaping air and dust; a dust extraction and collection system that expands upon said dust containment system by integrating a scroll shaped channel into the shroud and an outlet chute to extract and collect dust in a filtered dust bag and in which performance is increased by fins on the rotating implement driver and air inlet holes; a quick-release tool-less mechanism for attaching a rotating implement to the driveshaft with a hex shaped male/female interaction and push button release ball pin.
    Type: Application
    Filed: August 16, 2018
    Publication date: February 21, 2019
    Inventors: Jeremy Michael HAHNE, Seth ALBERTY, Bernardo J. HERZER, David KOSTKA, Mike SPANN, Jeremy Alexander PENDER
  • Publication number: 20170204063
    Abstract: The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxy! group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(=O)—(OR3XOR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among: (IIa), (IIIa) or anyone of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of an inflammatory disease.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 20, 2017
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, Romain NAJMAN, Florence MAHUTEAU, Didier SCHERRER, Karim CHEBLI, Michael HAHNE
  • Publication number: 20110256090
    Abstract: The invention relates to methods for identifying genes involved in TRAIL-induced apoptosis, to inhibitors of the expression of genes inducing resistance of cells to TRAIL-induced apoptosis and to activators of the expression of a gene sensitizing cells to TRAIL-induced apoptosis. The invention also relates to methods for sensitizing cells to TRAIL-induced apoptosis, methods for treating hyperproliferative diseases, methods for determining the responsiveness of a subject suffering from a hyperproliferative disease to TRAIL, to pharmaceutical compositions comprising products capable of sensitizing cells to TRAIL-induced apoptosis, and to methods for determining the prognosis of a subject suffering from a hyperproliferative disease.
    Type: Application
    Filed: December 18, 2009
    Publication date: October 20, 2011
    Applicants: UNIVERSITE DE MONTPELLIER 2 SCIENCES ET TECHNIQUES, Centre National de la Pecherche Scientifique- CNRS, UNIVERSITE DE MONTPELLIER 1
    Inventors: Michael Hahne, Bernard Combe, Jacques Morel, Rachel Audo, Alica Knapik
  • Publication number: 20020095030
    Abstract: The invention relates to nucleic acid molecules that include at least one death effector domain, expression vectors the include these nucleic acid molecules, host cells transformed with such vectors, methods for expressing and/or isolating gene products with at least one death effector domain, and purified or isolated gene products or fragments of these gene products that include at least one death effector domain.
    Type: Application
    Filed: September 30, 1999
    Publication date: July 18, 2002
    Inventors: JURG TSCHOPP, MARGOT THOME, KIMBERLY BURNS, MARTEN IRMLER, MICHAEL HAHNE, MICHAEL SCHROTER, PASCAL SCHNEIDER, JEAN-LUC BODMER, VERONIQUE STEINER, DONATA RIMOLDI, KAY HOFMANN, E. LARS FRENCH